[go: up one dir, main page]

WO2000066620A3 - Morphogen-induced enhancement of fertility - Google Patents

Morphogen-induced enhancement of fertility Download PDF

Info

Publication number
WO2000066620A3
WO2000066620A3 PCT/US2000/011501 US0011501W WO0066620A3 WO 2000066620 A3 WO2000066620 A3 WO 2000066620A3 US 0011501 W US0011501 W US 0011501W WO 0066620 A3 WO0066620 A3 WO 0066620A3
Authority
WO
WIPO (PCT)
Prior art keywords
fertility
morphogen
compositions
induced enhancement
provides methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/011501
Other languages
French (fr)
Other versions
WO2000066620A2 (en
Inventor
Kuber S Sampath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creative Biomolecules Inc
Original Assignee
Creative Biomolecules Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Biomolecules Inc filed Critical Creative Biomolecules Inc
Priority to AU46766/00A priority Critical patent/AU4676600A/en
Priority to CA002371695A priority patent/CA2371695A1/en
Priority to EP00928544A priority patent/EP1181041A2/en
Publication of WO2000066620A2 publication Critical patent/WO2000066620A2/en
Publication of WO2000066620A3 publication Critical patent/WO2000066620A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention provides methods and compositions for the treatment of human infertility, using the administration of morphogens to regulate ovarian follicle growth. The invention further provides methods and compositions to delay the onset or alleviate symptoms of menopause, and methods and compositions to decrease fertility.
PCT/US2000/011501 1999-04-30 2000-04-28 Morphogen-induced enhancement of fertility Ceased WO2000066620A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU46766/00A AU4676600A (en) 1999-04-30 2000-04-28 Morphogen-induced enhancement of fertility
CA002371695A CA2371695A1 (en) 1999-04-30 2000-04-28 Morphogen-induced enhancement of fertility
EP00928544A EP1181041A2 (en) 1999-04-30 2000-04-28 Morphogen-induced enhancement of fertility

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13172199P 1999-04-30 1999-04-30
US60/131,721 1999-04-30
US56117100A 2000-04-27 2000-04-27
US09/561,171 2000-04-27

Publications (2)

Publication Number Publication Date
WO2000066620A2 WO2000066620A2 (en) 2000-11-09
WO2000066620A3 true WO2000066620A3 (en) 2001-01-18

Family

ID=26829736

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/011501 Ceased WO2000066620A2 (en) 1999-04-30 2000-04-28 Morphogen-induced enhancement of fertility

Country Status (4)

Country Link
EP (1) EP1181041A2 (en)
AU (1) AU4676600A (en)
CA (1) CA2371695A1 (en)
WO (1) WO2000066620A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399676B2 (en) 2013-05-06 2016-07-26 Scholar Rock, Inc. Compositions and methods for growth factor modulation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ519330A (en) * 2002-05-30 2004-12-24 George Henry Davis New sequences for altering mammalian ovarian function and ovulation rate

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005751A2 (en) * 1991-08-30 1993-04-01 Creative Biomolecules, Inc. Osteogenic proteins in the treatment of bone deseases
WO1995010539A1 (en) * 1993-10-08 1995-04-20 The Johns Hopkins University School Of Medicine Growth differentiation factor-10
WO1997032033A1 (en) * 1996-02-28 1997-09-04 Vanderbilt University Compositions and methods of making embryonic stem cells
US5700911A (en) * 1993-05-12 1997-12-23 Genetics Institute, Inc. Bone morphogenetic protein -11 (BMP-11) compositions
WO1998012322A1 (en) * 1996-09-18 1998-03-26 Genetics Institute, Inc. Bone morphogenetic protein-16 (bmp-16) compositions
WO1998054572A1 (en) * 1997-05-30 1998-12-03 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
WO1999017797A1 (en) * 1997-10-06 1999-04-15 The Johns Hopkins University School Of Medicine Use of growth differenciation factor-9 (gdf-9) as a contraceptive

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005751A2 (en) * 1991-08-30 1993-04-01 Creative Biomolecules, Inc. Osteogenic proteins in the treatment of bone deseases
US5700911A (en) * 1993-05-12 1997-12-23 Genetics Institute, Inc. Bone morphogenetic protein -11 (BMP-11) compositions
WO1995010539A1 (en) * 1993-10-08 1995-04-20 The Johns Hopkins University School Of Medicine Growth differentiation factor-10
WO1997032033A1 (en) * 1996-02-28 1997-09-04 Vanderbilt University Compositions and methods of making embryonic stem cells
WO1998012322A1 (en) * 1996-09-18 1998-03-26 Genetics Institute, Inc. Bone morphogenetic protein-16 (bmp-16) compositions
WO1998054572A1 (en) * 1997-05-30 1998-12-03 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
WO1999017797A1 (en) * 1997-10-06 1999-04-15 The Johns Hopkins University School Of Medicine Use of growth differenciation factor-9 (gdf-9) as a contraceptive

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUBE JENNIFER L ET AL: "The bone morphogenetic protein 15 gene is X-linked and expressed in oocytes.", MOLECULAR ENDOCRINOLOGY, vol. 12, no. 12, December 1998 (1998-12-01), pages 1809 - 1817, XP000960764, ISSN: 0888-8809 *
HAYASHI MASARU ET AL: "Recombinant Growth Differentiation Factor-9 (GDF-9) enhances growth and differentiation of cultured early ovarian follicles", ENDOCRINOLOGY,US,BALTIMORE, MD, vol. 140, no. 3, March 1999 (1999-03-01), pages 1236 - 1244, XP002133258, ISSN: 0013-7227 *
SHIMASAKI SHUNICHI ET AL: "A functional bone morphogenetic protein system in the ovary.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 13, 22 June 1999 (1999-06-22), June 22, 1999, pages 7282 - 7287, XP002152947, ISSN: 0027-8424 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399676B2 (en) 2013-05-06 2016-07-26 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US9573995B2 (en) 2013-05-06 2017-02-21 Scholar Rock, Inc. Compositions and methods for growth factor modulation

Also Published As

Publication number Publication date
EP1181041A2 (en) 2002-02-27
AU4676600A (en) 2000-11-17
CA2371695A1 (en) 2000-11-09
WO2000066620A2 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
MXPA03009439A (en) 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity.
WO2000008015A3 (en) Fsh mimetics for the treatment of infertility
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
MXPA04002583A (en) Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity.
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
CA2505128A1 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2000038663A3 (en) Ep4 receptor agonists for treatment of dry eye
YU23102A (en) Compounds for the treatment of ischemia
EP0911321A3 (en) Compounds for the treatment of osteoporosis
AU2275397A (en) Troponin subunits and fragments useful as angiogenesis inhibitors
WO1998058911A3 (en) Prostaglandin agonists
GB0102672D0 (en) Compounds
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO1999058674A3 (en) Method of inhibiting osteoclast activity
GB0111186D0 (en) Novel compounds
WO2001001974A3 (en) Naaladase inhibitors in anxiety and memory disorders
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
CA2334257A1 (en) Treatment of osteoporosis with ep2/ep4 receptor selective agonists
MXPA04010307A (en) 5-oxo and 5-thio derivatives of 5h-indeno'1,2-bipyridine with adenosine a2a receptor binding and phosphodiesterase inhibiting activity for the treatment of neurodegenerative disorders and inflammation related diseases.
EP1032556A4 (en) Pharmaceutically active compounds and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2371695

Country of ref document: CA

Ref country code: CA

Ref document number: 2371695

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 615649

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 46766/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000928544

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000928544

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000928544

Country of ref document: EP